CCL21 and metabolic dysfunction-associated steatotic liver disease: Recently, research targeting the SLC protein family for therapeutic purposes has gradually increased, with small-molecule inhibitors or activators of SLC proteins being developed to treat various diseases, such as diabetes, NAFLD, and certain types of cancer.